{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-005503","form_type":"8-K","ticker":"CYTK","cik":"0001061983","company_name":"CYTOKINETICS INC","filed_at":"2023-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.740262+00:00","generated_at":"2026-06-18T16:55:38.587497+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cytokinetics Q4 net loss $137.4M; FDA rejects omecamtiv mecarbil NDA","bullets":["Net loss Q4 2022 $137.4M ($1.45/share) vs $30.6M ($0.36/share) in Q4 2021; full year loss $389.0M ($4.33/share).","FDA issued Complete Response Letter for omecamtiv mecarbil NDA, citing insufficient evidence from GALACTIC-HF.","Cash, cash equivalents and investments $829.3M at Dec 31, 2022; 2023 guidance: revenue up to $5M, operating expenses $420-450M.","SEQUOIA-HCM (aficamten) enrollment complete in Q2 2023 with results expected Q4 2023; second interim analysis of COURAGE-ALS in Q2 2023.","R&D expenses $75.0M in Q4 2022, up from $43.5M in Q4 2021; G&A $54.0M vs $33.8M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-005503","json":"https://secwatch.observer/filing/0000950170-23-005503.json","markdown":"https://secwatch.observer/filing/0000950170-23-005503.md","text":"https://secwatch.observer/filing/0000950170-23-005503.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1061983/000095017023005503/0000950170-23-005503-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1061983/000095017023005503/cytk-20230301.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T16:55:38.587497+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"85eb02ce0f933f25057f7ed4096bb3fee53a1eb3","claim":"CYTOKINETICS INC reported the fourth quarter and full year 2022 results: net income Net loss for the fourth quarter was $137.4 million or $1.45 per share and the net loss for the year 2022 was $389.0 mill.","evidence_excerpt":"On March 1, 2023, Cytokinetics, Incorporated announced its financial results for the fourth quarter and for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000095017023005503/0000950170-23-005503-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year 2022"},{"label":"Net income","value":"Net loss for the fourth quarter was $137.4 million or $1.45 per share and the net loss for the year 2022 was $389.0 mill"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}